American College of Rheumatology Releases Rheumatoid Arthritis Treatment Guidelines for Patients with Cancer

Posted on January 5th, 2016 by

The ACR 2015 Rheumatoid Arthritis (RA) treatment guidelines were published after nearly a year of review and revision by the panel. The guideline committee recommends that individuals with RA and cancer be treated in the following manner:

Previous Melanoma and Non-Melanoma Skin Cancer: Established RA patients with moderate or high disease activity and a history of previously treated or untreated skin cancer (melanoma or non-melanoma) are conditionally recommended to be treated with disease modifying anti-rheumatic drug (DMARD) therapy over biologics or tofacitinib.

Previous Lymphoproliferative Disorders: Established RA patients with moderate or high disease activity and a history of a previously treated lymphoproliferative disorder are strongly recommended to be treated with rituximab, rather than a TNFi and conditionally recommended to be treated with combination DMARD therapy, abatacept or tocilizumab rather than TNFi.

Previous Solid Organ Cancer: Established RA patients with moderate or high disease activity and a previously treated solid organ cancer are conditionally recommended to be treated for RA just as one would treat an RA patient without a history of solid organ cancer.

Source: American College of Rheumatology press release. 2015 ACR Guideline for the Treatment of Rheumatoid Arthritis Now Available Online. Nov. 10, 2015.

Copyright © 2016 CancerConnect. All Rights Reserved.

Tags: ACR, All Cancer Types, cancer, guidelines, News, RA, rheumatoid arthritis, treatment

You must be logged-in to the site to post a comment.